Revolution Medicines, Inc.
Company Stats
- Market Cap
- $44.0B
- as of Sep 30, 2026
- Shares Outstanding
- 214.3M
- Free Float
- 92.7%
Income Statement
- Revenue
- $0
- Operating Income
- -$1.2B
- Net Income
- -$1.1B
- EBITDA
- -$1.2B
Cash Flow
- Free Cash Flow
- -$913.7M
- FCF Yield
- -2.1%
- Owner FCF Yield
- -2.3%
Balance Sheet
- Cash & Equivalents
- $383.7M
Returns & Capital
- SBC, 3Y Avg
- $86.5M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $0 | -$913.7M | — |
| FY2024 | $0 | -$567.7M | — |
| FY2023 | $11.6M | -$358.3M | -3094.1% |
| FY2022 | $35.4M | -$235.2M | -664.8% |
| FY2021 | $29.4M | -$153.7M | -523.0% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 1, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back